New Immune-Stimulating Therapy Approved by FDA for Multiple Myeloma Treatment
An estimated 26,850 people will be diagnosed with multiple myeloma and 11,240 will die from this type of cancer in 2015. Multiple myeloma is a cancer of the blood that impairs plasma cells in the bone marrow necessary for fighting infections. When this cancer develops, healthy infection-fighting cells are pushed out of the bone marrow, leaving the patient more prone to illnesses due to a weakened immune system.
Recently, the U.S. Food and Drug Administration (FDA) approved a new therapy for treating multiple myeloma using Empliciti (elotuzumab) along with Revlimid (lenalidomide) and dexamethasone. This new therapy uses Empliciti to activate the immune system to kill the multiple myeloma cells along with help from the other two medications.
The therapy was tested for safety in a randomized clinical study of 646 multiple myeloma patients whose condition returned or did not respond to previous types of standard treatment. The participants who were treated using the Empliciti therapy experienced a 19.4 month delay in the worsening of their symptoms, while those who only received the Revlimid and dexamethasone only saw a 14.9 month delay.
Empliciti does come with side effects that may impair a patient’s ability to perform substantial gainful activity. Some of the side effects include fatigue, nerve damage, nose and throat infections, and pneumonia. If these side effects become severe, they can cause further disability in addition to the conditions caused by multiple myeloma alone.
Multiple Myeloma Symptoms Can Qualify You for Social Security Disability Benefits
Multiple myeloma is just one of the many types of cancer that can qualify you for Social Security disability benefits. If your condition is severe enough to impair you from working, but your benefits claim was denied, contact us online or call us at 1-(800)-800-3332 to schedule a consultation with our disability advocates!